Page last updated: 2024-10-20

thiosulfates and Calcinosis

thiosulfates has been researched along with Calcinosis in 52 studies

Thiosulfates: Inorganic salts of thiosulfuric acid possessing the general formula R2S2O3.
thiosulfate(2-) : A divalent inorganic anion obtained by removal of both protons from thiosulfuric acid.

Calcinosis: Pathologic deposition of calcium salts in tissues.

Research Excerpts

ExcerptRelevanceReference
"In this case series, we retrospectively identified all patients treated with topical sodium thiosulfate (TST) for calcinosis cutis (CC) associated with underlying autoimmune connective tissue diseases at Mayo Clinic (Rochester, MN, USA) during the period 1 January 2012 to 27 June 2017."7.91Topical sodium thiosulfate for calcinosis cutis associated with autoimmune connective tissue diseases: the Mayo Clinic experience, 2012-2017. ( Davis, MDP; Ernste, FC; Ma, JE; Wetter, DA, 2019)
"We report the successful use of abatacept and sodium thiosulfate in a patient with severe recalcitrant juvenile dermatomyositis complicated by ulcerative skin disease and progressive calcinosis."7.78Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis. ( Arabshahi, B; Jones, OY; Rider, LG; Silverman, RA, 2012)
"We report a patient with diffuse systemic sclerosis who presented with two symmetrical plaques on both axillae, which caused pain and skin retraction."6.72Clinical and ultrasound response to intralesional sodium thiosulfate for the treatment of calcinosis cutis in the setting of systemic sclerosis. A case-based review. ( Corrales-Martínez, AF; Durán-Vian, C; Gómez-Fernández, C; González-López, MA; López-Sundh, AE; Quintana-Sancho, A; Reguero-DelCura, L, 2021)
"Calciphylaxis is associated with medial arteriolar vascular calcification and results in ischemic subcutaneous necrosis with vulnerable skin ulcerations and high mortality."6.43Vascular ossification-calcification in metabolic syndrome, type 2 diabetes mellitus, chronic kidney disease, and calciphylaxis-calcific uremic arteriolopathy: the emerging role of sodium thiosulfate. ( Hayden, MR; Khanna, R; Kolb, L; Sowers, JR; Tyagi, SC, 2005)
"Treatment with sodium thiosulfate provides good results; however, intralesional and intravenous treatment can be limited by its adverse effects."5.72Therapeutic success of sodium thiosulfate in treating cutaneous calciphylaxis in a patient with hyperphosphataemic familial tumoral calcinosis. ( Gómez, C; Morales, P; Requena, S; Santos-Juanes, J, 2022)
"Pseudopseudohypoparathyroidism is an imprinted GNAS spectrum disorder that induces the phenotype of Albright's hereditary osteodystrophy."5.72Intralesional sodium thiosulfate treatment of calcinosis cutis in pseudopseudohypoparathyroidism. ( Brokamp, G; Mosser-Goldfarb, J, 2022)
"Hyperphosphatemic familial tumoral calcinosis (HFTC) is a rare autosomal recessive disorder."5.72The Successful Treatment of Deep Soft-tissue Calcifications with Topical Sodium Thiosulphate and Acetazolamide in a Boy with Hyperphosphatemic Familial Tumoral Calcinosis due to a Novel Mutation in ( Döneray, H; Gürbüz, K; Özden, A, 2022)
"Familial hyperphosphatemic tumoral calcinosis is a rare disorder characterized by hyperphosphatemia with recurrent ectopic periarticular calcifications, in addition to other visceral and vascular manifestations, without any inflammatory or neoplastic disorder."5.62Familial hyperphosphatemic tumoral calcinosis in an unusual and usual sites and dramatic improvement with the treatment of acetazolamide, sevelamer and topical sodium thiosulfate. ( Aktasoglu, E; Emecen Sanli, M; Ezgu, F; Inci, A; Kilic, A; Okur, I; Tumer, L, 2021)
" Numerous side-effects prompted dosage adjustment to 10 g intravenously daily."5.56Severe early-onset manifestations of pseudoxanthoma elasticum resulting from the cumulative effects of several deleterious mutations in ENPP1, ABCC6 and HBB: transient improvement in ectopic calcification with sodium thiosulfate. ( Bourrat, E; Kauffenstein, G; Leftheriotis, G; Martin, L; Navasiolava, N; Nitschke, Y; Omarjee, L; Rutsch, F; Vanakker, OM; Verschuere, S; Vignon, MD, 2020)
"The calcinosis was recalcitrant to treatment with topical steroids and hydroxychloroquine."5.51Linear amyopathic dermatomyositis with calcinosis cutis responsive to topical sodium thiosulfate. ( Frigerio, A; Haynes, D; Hull, C; Topham, C, 2019)
"Available treatments for calcinosis cutis are unsatisfactory, but given the recent use of topical and intralesional sodium thiosulfate (STS) to treat calcifying disorders, we sought to describe the use of intravenous (IV) STS for CTD-associated dystrophic calcinosis cutis."5.48Lack of response to intravenous sodium thiosulfate in three cases of extensive connective tissue disease-associated calcinosis cutis. ( Costner, M; Fett, NM; Lin, J; Merola, JF; Song, P; Vleugels, RA, 2018)
"However, its effect on tumoral calcinosis (TC) complicating autoimmune connective-tissue diseases has been scarcely described."5.46Intravenous sodium thiosulfate for treating tumoral calcinosis associated with systemic disorders: Report of four cases. ( Bardin, T; Ea, HK; Guigonis, V; Mageau, A; Ratzimbasafy, V; Richette, P; Urena, P, 2017)
"Hyperphosphatemic familial tumoral calcinosis (HFTC) and hyperphosphatemia hyperostosis syndrome (HHS) are rare diseases characterized by hyperphosphatemia and ectopic calcifications or recurrent episodes of diaphysitis."5.43Topical Sodium Thiosulfate: A Treatment for Calcifications in Hyperphosphatemic Familial Tumoral Calcinosis? ( Bahans, C; Benistan, K; Courbebaisse, M; Guigonis, V; Jost, J; Lienhardt, A; Linglart, A; Mutar, H; Pfender, E; Ratsimbazafy, V; Tran, TA, 2016)
" Sodium thiosulfate (STS) has recently been used with success in the treatment of tumoral calcinosis."5.34Tolerance and effect of sodium thiosulfate in calcific tendinitis of the rotator cuff. ( Bertrand-Vasseur, A; Darrieurtort-Laffite, C; Garraud, T; Le Goff, B; Planche, L, 2020)
"In this case series, we retrospectively identified all patients treated with topical sodium thiosulfate (TST) for calcinosis cutis (CC) associated with underlying autoimmune connective tissue diseases at Mayo Clinic (Rochester, MN, USA) during the period 1 January 2012 to 27 June 2017."3.91Topical sodium thiosulfate for calcinosis cutis associated with autoimmune connective tissue diseases: the Mayo Clinic experience, 2012-2017. ( Davis, MDP; Ernste, FC; Ma, JE; Wetter, DA, 2019)
"We report the successful use of abatacept and sodium thiosulfate in a patient with severe recalcitrant juvenile dermatomyositis complicated by ulcerative skin disease and progressive calcinosis."3.78Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis. ( Arabshahi, B; Jones, OY; Rider, LG; Silverman, RA, 2012)
"We recommend topical sodium thiosulfate 25% as an alternative treatment for dystrophic calcinosis cutis."3.77A novel treatment for ulcerative calcinosis cutis. ( Bair, B; Fivenson, D, 2011)
"We report a patient with diffuse systemic sclerosis who presented with two symmetrical plaques on both axillae, which caused pain and skin retraction."2.72Clinical and ultrasound response to intralesional sodium thiosulfate for the treatment of calcinosis cutis in the setting of systemic sclerosis. A case-based review. ( Corrales-Martínez, AF; Durán-Vian, C; Gómez-Fernández, C; González-López, MA; López-Sundh, AE; Quintana-Sancho, A; Reguero-DelCura, L, 2021)
"We have limited data on the treatment of calcinosis cutis associated with systemic sclerosis and dermatomyositis."2.66Treatment of calcinosis cutis in systemic sclerosis and dermatomyositis: A review of the literature. ( Aggarwal, R; Arnaud, L; Barbaud, A; Chasset, F; Chizzolini, C; Francès, C; Monfort, JB; Oddis, CV; Senet, P; Traineau, H, 2020)
"Calciphylaxis is defined as calcification of the media of small- and medium-sized blood vessels in the dermis and subcutaneous tissue."2.52Calcinosis Cutis and Calciphylaxis. ( Jiménez-Gallo, D; Linares-Barrios, M; Ossorio-García, L, 2015)
"Calciphylaxis is associated with medial arteriolar vascular calcification and results in ischemic subcutaneous necrosis with vulnerable skin ulcerations and high mortality."2.43Vascular ossification-calcification in metabolic syndrome, type 2 diabetes mellitus, chronic kidney disease, and calciphylaxis-calcific uremic arteriolopathy: the emerging role of sodium thiosulfate. ( Hayden, MR; Khanna, R; Kolb, L; Sowers, JR; Tyagi, SC, 2005)
"Pseudopseudohypoparathyroidism is an imprinted GNAS spectrum disorder that induces the phenotype of Albright's hereditary osteodystrophy."1.72Intralesional sodium thiosulfate treatment of calcinosis cutis in pseudopseudohypoparathyroidism. ( Brokamp, G; Mosser-Goldfarb, J, 2022)
"Hyperphosphatemic familial tumoral calcinosis (HFTC) is a rare autosomal recessive disorder."1.72The Successful Treatment of Deep Soft-tissue Calcifications with Topical Sodium Thiosulphate and Acetazolamide in a Boy with Hyperphosphatemic Familial Tumoral Calcinosis due to a Novel Mutation in ( Döneray, H; Gürbüz, K; Özden, A, 2022)
"Treatment with sodium thiosulfate provides good results; however, intralesional and intravenous treatment can be limited by its adverse effects."1.72Therapeutic success of sodium thiosulfate in treating cutaneous calciphylaxis in a patient with hyperphosphataemic familial tumoral calcinosis. ( Gómez, C; Morales, P; Requena, S; Santos-Juanes, J, 2022)
"Familial hyperphosphatemic tumoral calcinosis is a rare disorder characterized by hyperphosphatemia with recurrent ectopic periarticular calcifications, in addition to other visceral and vascular manifestations, without any inflammatory or neoplastic disorder."1.62Familial hyperphosphatemic tumoral calcinosis in an unusual and usual sites and dramatic improvement with the treatment of acetazolamide, sevelamer and topical sodium thiosulfate. ( Aktasoglu, E; Emecen Sanli, M; Ezgu, F; Inci, A; Kilic, A; Okur, I; Tumer, L, 2021)
" Numerous side-effects prompted dosage adjustment to 10 g intravenously daily."1.56Severe early-onset manifestations of pseudoxanthoma elasticum resulting from the cumulative effects of several deleterious mutations in ENPP1, ABCC6 and HBB: transient improvement in ectopic calcification with sodium thiosulfate. ( Bourrat, E; Kauffenstein, G; Leftheriotis, G; Martin, L; Navasiolava, N; Nitschke, Y; Omarjee, L; Rutsch, F; Vanakker, OM; Verschuere, S; Vignon, MD, 2020)
"The calcinosis was recalcitrant to treatment with topical steroids and hydroxychloroquine."1.51Linear amyopathic dermatomyositis with calcinosis cutis responsive to topical sodium thiosulfate. ( Frigerio, A; Haynes, D; Hull, C; Topham, C, 2019)
"Available treatments for calcinosis cutis are unsatisfactory, but given the recent use of topical and intralesional sodium thiosulfate (STS) to treat calcifying disorders, we sought to describe the use of intravenous (IV) STS for CTD-associated dystrophic calcinosis cutis."1.48Lack of response to intravenous sodium thiosulfate in three cases of extensive connective tissue disease-associated calcinosis cutis. ( Costner, M; Fett, NM; Lin, J; Merola, JF; Song, P; Vleugels, RA, 2018)
"Calcium gluconate extravasation is a process that can cause serious lesions, such as necrosis and calcification of the soft tissues."1.48The Use of Antidotes for Calcium Gluconate Extravasation: An Experimental Study in Mice. ( Centeno Cortés, A; de Toro Santos, FJ; López San Martín, P; Midón Míguez, J; Mosquera Osés, JJ; Pacheco Compaña, FJ; Yebra-Pimentel Vidal, MT, 2018)
"However, its effect on tumoral calcinosis (TC) complicating autoimmune connective-tissue diseases has been scarcely described."1.46Intravenous sodium thiosulfate for treating tumoral calcinosis associated with systemic disorders: Report of four cases. ( Bardin, T; Ea, HK; Guigonis, V; Mageau, A; Ratzimbasafy, V; Richette, P; Urena, P, 2017)
"Hyperphosphatemic familial tumoral calcinosis (HFTC) and hyperphosphatemia hyperostosis syndrome (HHS) are rare diseases characterized by hyperphosphatemia and ectopic calcifications or recurrent episodes of diaphysitis."1.43Topical Sodium Thiosulfate: A Treatment for Calcifications in Hyperphosphatemic Familial Tumoral Calcinosis? ( Bahans, C; Benistan, K; Courbebaisse, M; Guigonis, V; Jost, J; Lienhardt, A; Linglart, A; Mutar, H; Pfender, E; Ratsimbazafy, V; Tran, TA, 2016)
"ESRD was secondary to nephronophthisis (n = 1), membranoproliferative glomerulonephritis (n = 1), diabetic nephropathy (n = 1), and thrombotic microangiopathy (n = 1)."1.40Sodium thiosulphate treatment of uraemic tumoral calcinosis. ( Bardin, T; Cohen-Solal, M; Ea, HK; Lioté, F; Malbos, S; Trout, H; Urena-Torres, P, 2014)
"Treatment with sodium thiosulfate (STS) and hyperbaric oxygen (HBO) therapy alone was ineffective, forcing the patient to undergo bilateral below the-knee-amputation (BKA) 5 months after presentation."1.36Successful treatment of calcific uremic arteriolopathy in a pediatric dialysis patient. ( Amin, N; Gonzalez, E; Lieber, M; Salusky, IB; Zaritsky, JJ, 2010)
"Treatment with sodium thiosulfate resulted in dramatic scintigraphic improvement."1.35Bone scan findings in metastatic calcification from calciphylaxis. ( Leslie, WD; Soni, S, 2008)
"Sodium thiosulfate treatment transiently lowered plasma ionized calcium and induced metabolic acidosis."1.35Sodium thiosulfate prevents vascular calcifications in uremic rats. ( Farese, S; Frey, BM; Frey, FJ; Huynh-Do, U; Pasch, A; Schaffner, T, 2008)

Research

Studies (52)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (3.85)18.2507
2000's6 (11.54)29.6817
2010's27 (51.92)24.3611
2020's17 (32.69)2.80

Authors

AuthorsStudies
Ricardo, JW1
Sun, HY1
Gorji, M1
Sebaratnam, DF1
Requena, S1
Santos-Juanes, J1
Morales, P1
Gómez, C1
Brokamp, G1
Mosser-Goldfarb, J1
Le, Q1
Robinson, A1
Stevens, W1
Li, J2
Tubau, C1
Cubiró, X1
Amat-Samaranch, V1
Garcia-Melendo, C1
Puig, L1
Roé-Crespo, E1
Bhari, N1
Bharti, P1
Omarjee, L1
Nitschke, Y1
Verschuere, S1
Bourrat, E1
Vignon, MD1
Navasiolava, N1
Leftheriotis, G1
Kauffenstein, G1
Rutsch, F1
Vanakker, OM1
Martin, L1
Darrieurtort-Laffite, C1
Bertrand-Vasseur, A1
Garraud, T1
Planche, L1
Le Goff, B1
Boyce, AM1
Gafni, RI1
Ferreira, CR1
Yan, M1
Ren, L1
Deng, H1
Wen, R1
Howard, RM1
Smith, GP2
von Hodenberg, C1
Neufeld, M1
Wohlrab, J1
Meyer, D1
Ehrchen, J1
Sunderkötter, C1
Badawi, AH1
Patel, V1
Warner, AE1
Hall, JC1
López-Sundh, AE1
Quintana-Sancho, A1
Durán-Vian, C1
Reguero-DelCura, L1
Corrales-Martínez, AF1
Gómez-Fernández, C1
González-López, MA1
Döneray, H1
Özden, A1
Gürbüz, K1
Emecen Sanli, M1
Kilic, A1
Aktasoglu, E1
Inci, A1
Okur, I1
Ezgu, F1
Tumer, L1
Müller, C1
Tanew, A1
Laml-Wallner, G1
Radakovic, S1
García-García, E1
López-López, R1
Álvarez-Del-Vayo, C1
Bernabeu-Wittel, J1
Gunasekera, NS1
Maniar, LEG1
Lezcano, C1
Laga, AC1
Merola, JF2
Song, P1
Fett, NM1
Lin, J1
Costner, M1
Vleugels, RA1
Goossens, J1
Courbebaisse, M2
Caudron, E1
Bahans, C3
Vacquerie, V1
Melchior, J1
Salle, PV1
Moesch, C1
Daudon, M1
Frocht, V1
Richette, P2
Ea, HK3
Guigonis, V4
Fiel, DC1
Margarido Malvar, HB1
Dias Silva, RA1
Rosenbach, M1
Pacheco Compaña, FJ1
Midón Míguez, J1
de Toro Santos, FJ1
Centeno Cortés, A1
López San Martín, P1
Yebra-Pimentel Vidal, MT1
Mosquera Osés, JJ1
Ma, JE1
Ernste, FC1
Davis, MDP1
Wetter, DA1
Topham, C1
Haynes, D1
Frigerio, A1
Hull, C1
Rodelo-Haad, C1
Esquivias-Motta, E1
Amaral-Neiva, F1
Martin-Malo, A1
Aljama, P1
Rodriguez, M1
Taillé, C1
Debray, MP1
Danel, C1
Serhal, A1
Pradère, P1
Crestani, B1
Traineau, H1
Aggarwal, R1
Monfort, JB1
Senet, P1
Oddis, CV1
Chizzolini, C1
Barbaud, A1
Francès, C1
Arnaud, L1
Chasset, F1
Christie, M1
Roscoe, J1
Chee, J1
Inparajah, M1
Vaughn-Neil, T1
Nagai, G1
Ng, P1
Fung, J1
Ting, R1
Tam, P1
Sikaneta, T1
Malbos, S1
Urena-Torres, P1
Cohen-Solal, M1
Trout, H1
Lioté, F1
Bardin, T2
Baumgartner-Nielsen, J1
Olesen, AB1
Jiménez-Gallo, D1
Ossorio-García, L1
Linares-Barrios, M1
Young, G1
Putt, T1
Schollum, J1
Walker, R1
Jost, J1
Tran, TA1
Linglart, A1
Benistan, K1
Lienhardt, A1
Mutar, H1
Pfender, E1
Ratsimbazafy, V2
Mageau, A1
Ratzimbasafy, V1
Urena, P1
Soni, S1
Leslie, WD1
Pasch, A1
Schaffner, T1
Huynh-Do, U1
Frey, BM1
Frey, FJ1
Farese, S1
O'Neill, WC2
Wolf, EK1
Smidt, AC1
Laumann, AE1
Amin, N1
Gonzalez, E1
Lieber, M1
Salusky, IB1
Zaritsky, JJ1
Adirekkiat, S1
Sumethkul, V1
Ingsathit, A1
Domrongkitchaiporn, S1
Phakdeekitcharoen, B1
Kantachuvesiri, S1
Kitiyakara, C1
Klyprayong, P1
Disthabanchong, S1
Park, YH1
Park, CH1
Kim, HJ1
Lomashvili, KA1
Bair, B1
Fivenson, D1
Arabshahi, B1
Silverman, RA1
Jones, OY1
Rider, LG1
Hayden, MR1
Tyagi, SC1
Kolb, L1
Sowers, JR1
Khanna, R1
Tokashiki, K1
Ishida, A1
Kouchi, M1
Ishihara, S1
Tomiyama, N1
Kohagura, K1
Iseki, K1
Takishita, S1
Papadakis, JT1
Patrikarea, A1
Digenis, GE1
Stamatelou, K1
Ntaountaki, I1
Athanasopoulos, V1
Tamvakis, N1
Kyriakopoulos, G1
Kontogianni, K1

Clinical Trials (5)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Randomized Placebo-controlled Trial of the Safety and Efficacy of Topical Sodium Metabisulfite for the Treatment of Calcinosis in Patients With Systemic Sclerosis.[NCT06155578]Phase 1/Phase 220 participants (Anticipated)Interventional2024-01-02Not yet recruiting
Efficacy and Tolerance of Sodium Thiosulfate Injection After Ultrasound-guided Percutaneous Irrigation of Calcific Tendinopathy of the Rotator Cuff[NCT02538939]Phase 217 participants (Actual)Interventional2015-12-02Completed
A Pilot Study to Evaluate Topical Sodium Thiosulfate Therapy for Calcinosis Cutis (STS-CALC)[NCT01918904]Phase 20 participants (Actual)Interventional2013-09-30Withdrawn (stopped due to PI decided not to proceed with this project. No participants were enrolled.)
A Randomized, Controlled Pilot Trial to Evaluate the Efficacy and Safety of Subcutaneous Abatacept in Treating Interstitial Lung Disease Associated With the Anti-synthetase Syndrome[NCT03215927]Phase 220 participants (Actual)Interventional2017-06-01Active, not recruiting
Abatacept for the Treatment of Refractory Juvenile Dermatomyositis[NCT02594735]Phase 410 participants (Actual)Interventional2015-11-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Corticosteroid Dose for Steroid-sparing Benefit From Baseline to Week 24

"Patients who have achieved Definition of Improvement (DOI) at week 6 (visit 2) or at any point thereafter and is rated by their study physician as at least minimally improved, then tapering of corticosteroids may commence using a precise dose reduction schedule as follows:~For patients taking 40 to 60 mg daily, prednisone will be tapered by 10 mg ,For patients taking 20 to 35 mg daily, prednisone will be tapered by 5 mg. For patients taking 7.5 to 15 mg daily, prednisone will be tapered by 2.5 mg. For patients taking 1 to 5 mg daily, prednisone will be tapered by 1 mg For patients receiving intravenous pulse methylprednisolone therapy, they may alternatively reduce the dose of IV therapy, instead of oral by a decrease of 25%" (NCT02594735)
Timeframe: week 0 to week 24

Interventionmg (Mean)
Week 0 (Baseline)16.7
Week 2410.2

Improvement in Childhood Health Assessment Questionnaire (CHAQ) From Baseline to Week 24

Physical function will be measured by using the Stanford HAQ/CHAQ: Childhood Health Assessment Questionnaire: The Stanford HAQ is a brief self-report questionnaire assessing physical function pertaining to activities of daily living in a variety of domains. The CHAQ was adapted directly from the HAQ and it has also been successfully applied to patients with juvenile myositis, with scores ranging from 0 to 3. Lower scores indicate less physical disability. (NCT02594735)
Timeframe: week 0 to 24

Interventionunits on a scale (Mean)
Week 0 (Baseline)1.84
Week 240.88

Improvement in Cutaneous Disease Activity From Baseline to Week 24

Cutaneous disease activity will be measured using the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI). CDASI is a clinician-scored instrument that separately measures activity and damage in the skin of dermatomyositis patients for use in clinical practice or clinical/therapeutic studies. Cutaneous disease activity was measured via the activity sub-score of CDASI, ranging from 0-100. Higher scores indicate more disease activity. (NCT02594735)
Timeframe: week 0 to week 24

Interventionscore on a scale (Mean)
Week 0 (Baseline)21.4
Week 2414.0

Improvement in Extramuscular Activity From Baseline to Week 24

The extramuscular activity will be measured by using the Myositis Disease Activity Assessment Tool (MDAAT). This validated tool measures the degree of disease activity of extra-muscular organ systems and muscle on a 0 - 10 cm visual analogue scale (VAS). Extramuscular activity ranges between 0 and 10 via VAS. Lower scores indicate lower disease activity. (NCT02594735)
Timeframe: week 0 to 24

Interventionunits on a scale (Mean)
Week 0 (Baseline)4.1
Week 242.4

Improvement in Manual Muscle Testing (MMT8) From Baseline to Week 24

Muscle strength will be measured using an abbreviated Manual Muscle Testing (MMT) in 8 muscles (MMT8) ranging between 0 and 10 for each muscle bilaterally (with the exception of neck flexors, for a total of 15 muscles) with a total score ranging between 0 and 150. Higher scores indicate higher muscle strength. (NCT02594735)
Timeframe: week 0 to week 24

Interventionunits on a scale (Mean)
Week 0 (Baseline)121.8
Week 24137.2

Improvement in Muscle Enzymes From Baseline to Week 24

"The muscle enzymes include creatine kinase (CK), aldolase, lactate dehydrogenase (LDH), alanine aminotransferase (ALT) and aspartate aminotransferase (AST). If more than one muscle enzyme is identified as being elevated (a minimum level of 1.3 x the upper limit of normal), then the most abnormal will be selected and this enzyme will be the target enzyme followed to evaluate disease improvement or worsening.~In order to standardize the change in muscle enzymes selected as most abnormal across patients, the outcome measurement was calculated as the most abnormal enzyme level measured via bloodwork divided by the upper limit normal of the healthy reference range (i.e percentage of the upper limit normal for the respective muscle enzyme). Higher percentages indicate higher muscle enzyme levels." (NCT02594735)
Timeframe: week 0 to 24

Interventionpercentage of upper limit normal (Mean)
Week 0 (Baseline)1.52
Week 241.52

Improvement in Parent/Patient Global Activity From Baseline to Week 24

This tool measures the global evaluation y the patient, or by the parent if the patient is a minor, of the patient's overall disease activity at the time of assessment using a 10 cm. visual analogue scale (VAS). Parent/Patient Global Activity ranges between 0 and 10 via VAS. Lower scores indicate less disease activity. (NCT02594735)
Timeframe: week 0 to 24

Interventionunits on a scale (Mean)
Week 0 (Baseline)5.3
Week 242.3

Improvement in Physician Global Activity From Baseline to Week 24

This tool measures the global evaluation by the treating physician of the overall disease activity of the patient at the time of assessment using a 10 cm visual analogue scale (VAS). Physician global activity ranges between 0 and 10 via VAS. Lower scores indicate less disease activity. (NCT02594735)
Timeframe: week 0 to week 24

Interventionunits on a scale (Mean)
Week 0 (Baseline)5.0
Week 242.6

Improvement in Total Muscle Edema by MRI From Baseline to Week 24

Axial STIR and T1 MRI images of bilateral thighs and pelvis were obtained at baseline and week 24. Images were coded and reviewed independently by two musculoskeletal radiologists who had comparable inter-observer variability and were blinded to any subject data, including visit number. MRI scoring was performed utilizing a 4-point scale (0-normal, 1-mild, 2-moderate, 3-severe) for muscle edema for each of the muscle groups examined, i.e. gluteal, adductors, hamstrings, and quadriceps, resulting in an aggregate score between 0 to 12. (NCT02594735)
Timeframe: week 0 to week 24

Interventionscore on a scale (Mean)
Week 0 (Baseline)5.3
Week 242.3

Total Improvement Score by IMACS Core Set Measures at Week 24

"The ACR-EULAR Response Criteria use a continuous total improvement score from baseline (range 0-100) based on the sum of the absolute percent change in the 6 core domains (weighted) used in the IMACS DOI (International Myositis Assessment and Clinical Studies definition of improvement)~IMACS core measures are: Physician Global Assessment of Disease Activity (PGA), Patient (Subject) Global Assessment of Disease Activity (SGA), Manual Muscle Test (MMT-8), Health Assessment Questionnaire-Disability Index (HAQ-DI), Muscle Enzyme levels, Myositis Disease Activity Assessment Tool (MDAAT) Extramuscular Global Activity.~In children, the total improvement score ranges between 0 and 100 percent corresponds to the degree of improvement, with higher scores corresponding to a greater degree of improvement ( >/= 30 represents minimal improvement, a score of >/= 45 represents moderate improvement, and a score of >/= 75 represents major improvement)." (NCT02594735)
Timeframe: week 0 to week 24

Interventionscore on a scale (Mean)
Open Label (One Arm)53.8

Number of Treatment-emergent Adverse Events

Safety will be assessed by review of adverse events using NCI Common Terminology criteria v5.0 November 2017. Particular attention to serious adverse events and infections will be given. An adverse event diary will be maintained throughout the study. Patient evaluations will include: vital sign measurement, physical examination, and laboratory parameters for hematology and routine chemistries (NCT02594735)
Timeframe: week 0 to week 24

Interventionevents (Number)
Worsening of interstitial lung diseaseCompression fractureRight knee contracture worseningWorsening calcinosisLipoatrophy, focalFebrile episodesSkin-infectionE. coli diarrhea
Open Label (One Arm)11121211

Reviews

8 reviews available for thiosulfates and Calcinosis

ArticleYear
Topical sodium thiosulfate as treatment of calcinosis cutis: Case series and systematic review.
    Journal of the American Academy of Dermatology, 2022, Volume: 87, Issue:2

    Topics: Calcinosis; Humans; Skin Diseases; Thiosulfates

2022
Generalized Arterial Calcification of Infancy: New Insights, Controversies, and Approach to Management.
    Current osteoporosis reports, 2020, Volume: 18, Issue:3

    Topics: Adenosine Monophosphate; Bone Density Conservation Agents; Calcinosis; Cardiovascular Agents; Chelat

2020
Clinical and ultrasound response to intralesional sodium thiosulfate for the treatment of calcinosis cutis in the setting of systemic sclerosis. A case-based review.
    Clinical rheumatology, 2021, Volume: 40, Issue:7

    Topics: Calcinosis; Humans; Scleroderma, Systemic; Skin Diseases; Thiosulfates

2021
Treatment of calcinosis cutis in systemic sclerosis and dermatomyositis: A review of the literature.
    Journal of the American Academy of Dermatology, 2020, Volume: 82, Issue:2

    Topics: Calcinosis; Dermatologic Surgical Procedures; Dermatomyositis; Diltiazem; Humans; Injections, Intral

2020
Calcinosis Cutis and Calciphylaxis.
    Actas dermo-sifiliograficas, 2015, Volume: 106, Issue:10

    Topics: Autoimmune Diseases; Calcinosis; Calciphylaxis; Calcium; Collagen Diseases; Diagnostic Imaging; Huma

2015
Treatment of vascular calcification.
    Kidney international, 2008, Volume: 74, Issue:11

    Topics: Animals; Calcinosis; Humans; Kidney Diseases; Renal Circulation; Thiosulfates; Vascular Diseases

2008
Recent progress in the treatment of vascular calcification.
    Kidney international, 2010, Volume: 78, Issue:12

    Topics: Animals; Calcinosis; Diphosphonates; Disease Models, Animal; Humans; Kidney Diseases; Thiosulfates;

2010
Vascular ossification-calcification in metabolic syndrome, type 2 diabetes mellitus, chronic kidney disease, and calciphylaxis-calcific uremic arteriolopathy: the emerging role of sodium thiosulfate.
    Cardiovascular diabetology, 2005, Mar-18, Volume: 4

    Topics: Animals; Antioxidants; Arteries; Atherosclerosis; Calcinosis; Calciphylaxis; Chelating Agents; Chron

2005

Trials

1 trial available for thiosulfates and Calcinosis

ArticleYear
Tolerance and effect of sodium thiosulfate in calcific tendinitis of the rotator cuff.
    Clinical rheumatology, 2020, Volume: 39, Issue:2

    Topics: Adult; Calcinosis; Chelating Agents; Female; Humans; Injections, Intralesional; Male; Middle Aged; P

2020

Other Studies

43 other studies available for thiosulfates and Calcinosis

ArticleYear
Therapeutic success of sodium thiosulfate in treating cutaneous calciphylaxis in a patient with hyperphosphataemic familial tumoral calcinosis.
    The Australasian journal of dermatology, 2022, Volume: 63, Issue:1

    Topics: Aged; Antioxidants; Calcinosis; Calciphylaxis; Humans; Hyperostosis, Cortical, Congenital; Hyperphos

2022
Intralesional sodium thiosulfate treatment of calcinosis cutis in pseudopseudohypoparathyroidism.
    Pediatric dermatology, 2022, Volume: 39, Issue:3

    Topics: Adolescent; Calcinosis; Humans; Pseudohypoparathyroidism; Pseudopseudohypoparathyroidism; Skin Neopl

2022
Recalcitrant digital calcinosis cutis successfully treated with intralesional sodium thiosulfate under digital nerve blockade.
    BMJ case reports, 2022, Apr-06, Volume: 15, Issue:4

    Topics: Calcinosis; Humans; Nerve Block; Quality of Life; Skin Diseases; Thiosulfates

2022
Clinical and ultrasonography follow-up of five cases of calcinosis cutis successfully treated with intralesional sodium thiosulfate.
    Journal of ultrasound, 2022, Volume: 25, Issue:4

    Topics: Calcinosis; Follow-Up Studies; Humans; Thiosulfates; Ultrasonography

2022
Dystrophic calcinosis cutis in autosomal recessive dystrophic epidermolysis bullosa.
    BMJ case reports, 2019, Sep-20, Volume: 12, Issue:9

    Topics: Administration, Topical; Calcinosis; Child; Epidermolysis Bullosa Dystrophica; Female; Genetic Couns

2019
Severe early-onset manifestations of pseudoxanthoma elasticum resulting from the cumulative effects of several deleterious mutations in ENPP1, ABCC6 and HBB: transient improvement in ectopic calcification with sodium thiosulfate.
    The British journal of dermatology, 2020, Volume: 183, Issue:2

    Topics: Calcinosis; Humans; Male; Multidrug Resistance-Associated Proteins; Mutation; Phenotype; Phosphoric

2020
Intravenous sodium thiosulfate combined with parathyroidectomy as a cure for uremic tumoral calcinosis in a hemodialysis patient.
    Joint bone spine, 2021, Volume: 88, Issue:1

    Topics: Calcinosis; Humans; Kidney Failure, Chronic; Parathyroidectomy; Renal Dialysis; Thiosulfates

2021
Treatment of calcinosis cutis with sodium thiosulfate therapy.
    Journal of the American Academy of Dermatology, 2020, Volume: 83, Issue:5

    Topics: Antioxidants; Calcinosis; Humans; Retrospective Studies; Skin Diseases; Thiosulfates

2020
Topical sodium thiosulfate: a reliable treatment for digital calcinosis cutis - a case series with six patients.
    Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2020, Volume: 18, Issue:10

    Topics: Calcinosis; Humans; Skin Diseases; Skin Neoplasms; Thiosulfates

2020
Dystrophic calcinosis cutis: treatment with intravenous sodium thiosulfate.
    Cutis, 2020, Volume: 106, Issue:2

    Topics: Administration, Intravenous; Calcinosis; Female; Humans; Middle Aged; Skin Diseases; Thiosulfates; T

2020
The Successful Treatment of Deep Soft-tissue Calcifications with Topical Sodium Thiosulphate and Acetazolamide in a Boy with Hyperphosphatemic Familial Tumoral Calcinosis due to a Novel Mutation in
    Journal of clinical research in pediatric endocrinology, 2022, 06-07, Volume: 14, Issue:2

    Topics: Acetazolamide; Calcinosis; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperosto

2022
Familial hyperphosphatemic tumoral calcinosis in an unusual and usual sites and dramatic improvement with the treatment of acetazolamide, sevelamer and topical sodium thiosulfate.
    Journal of pediatric endocrinology & metabolism : JPEM, 2021, Jun-25, Volume: 34, Issue:6

    Topics: Acetazolamide; Administration, Topical; Anticonvulsants; Antioxidants; Calcinosis; Chelating Agents;

2021
Successful treatment of calcinosis cutis with a topical sodium thiosulphate preparation containing 20% zinc oxide in a patient with sclerotic graft-versus-host disease.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2022, Volume: 36, Issue:1

    Topics: Calcinosis; Graft vs Host Disease; Humans; Skin Diseases; Thiosulfates; Zinc Oxide

2022
Iatrogenic Calcinosis Cutis Successfully Treated with Topical Sodium Thiosulfate.
    Pediatric dermatology, 2017, Volume: 34, Issue:3

    Topics: Administration, Topical; Calcinosis; Child; Humans; Iatrogenic Disease; Male; Skin Diseases; Thiosul

2017
Intralesional Sodium Thiosulfate Treatment for Calcinosis Cutis in the Setting of Lupus Panniculitis.
    JAMA dermatology, 2017, 09-01, Volume: 153, Issue:9

    Topics: Adult; Antioxidants; Calcinosis; Female; Humans; Injections, Intralesional; Panniculitis, Lupus Eryt

2017
Lack of response to intravenous sodium thiosulfate in three cases of extensive connective tissue disease-associated calcinosis cutis.
    The British journal of dermatology, 2018, Volume: 178, Issue:6

    Topics: Antioxidants; Calcinosis; Chelating Agents; Connective Tissue Diseases; Dermatologic Agents; Female;

2018
Efficacy of intralesional sodium thiosulfate injections for disabling tumoral calcinosis: Two cases.
    Seminars in arthritis and rheumatism, 2017, Volume: 47, Issue:3

    Topics: Adult; Calcinosis; Chelating Agents; Dermatomyositis; Female; Fibroblast Growth Factor-23; Humans; H

2017
The role of mammography in calcific uremic arteriolopathy.
    Kidney international, 2017, Volume: 92, Issue:3

    Topics: Aged; Arterioles; Biopsy; Calcinosis; Debridement; Diabetes Mellitus, Type 2; Diabetic Nephropathies

2017
Calcinosis cutis: a rock and a hard place.
    The British journal of dermatology, 2018, Volume: 178, Issue:6

    Topics: Calcinosis; Connective Tissue Diseases; Humans; Thiosulfates

2018
The Use of Antidotes for Calcium Gluconate Extravasation: An Experimental Study in Mice.
    Plastic and reconstructive surgery, 2018, Volume: 142, Issue:3

    Topics: Animals; Antidotes; Calcinosis; Calcium Gluconate; Hyaluronoglucosaminidase; Male; Mice; Mice, Inbre

2018
Topical sodium thiosulfate for calcinosis cutis associated with autoimmune connective tissue diseases: the Mayo Clinic experience, 2012-2017.
    Clinical and experimental dermatology, 2019, Volume: 44, Issue:5

    Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Arthritis, Juvenile; Arthriti

2019
Linear amyopathic dermatomyositis with calcinosis cutis responsive to topical sodium thiosulfate.
    Pediatric dermatology, 2019, Volume: 36, Issue:4

    Topics: Administration, Topical; Adolescent; Biopsy, Needle; Calcinosis; Chronic Disease; Dermatomyositis; H

2019
Reversing extraosseous calcifications. A case of breast uremic calcific arteriolopathy.
    The breast journal, 2019, Volume: 25, Issue:5

    Topics: Arterioles; Breast Diseases; Calcinosis; Ergocalciferols; Female; Humans; Kidney Failure, Chronic; M

2019
Calcium-solubilizing sodium thiosulfate failed to improve pulmonary alveolar microlithiasis: Evaluation of calcium content with CT scan.
    Respiratory medicine and research, 2019, Volume: 75

    Topics: Adult; Calcinosis; Calcium; Chelating Agents; Disease Progression; Female; Genetic Diseases, Inborn;

2019
Treatment of a hemodialysis patient with pulmonary calcification-associated progressive respiratory failure with sodium thiosulfate.
    Transplantation, 2013, Jul-15, Volume: 96, Issue:1

    Topics: Calcinosis; Chelating Agents; Humans; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle

2013
Intradermal sodium thiosulfate for exophytic calcinosis cutis of connective tissue disease.
    Journal of the American Academy of Dermatology, 2013, Volume: 69, Issue:3

    Topics: Adult; Calcinosis; Calcium; Chelating Agents; Dermatomyositis; Female; Humans; Injections, Intraderm

2013
Sodium thiosulphate treatment of uraemic tumoral calcinosis.
    Rheumatology (Oxford, England), 2014, Volume: 53, Issue:3

    Topics: Aged; Calcinosis; Comorbidity; Female; Humans; Hypertension; Incidence; Kidney Diseases; Kidney Fail

2014
Treatment of Skin Calcifications with Intra-lesional Injection of Sodium Thiosulphate: A Case Series.
    Acta dermato-venereologica, 2016, Volume: 96, Issue:2

    Topics: Aged; Calcinosis; Dermatologic Agents; Female; Humans; Injections, Intradermal; Injections, Intrales

2016
Tumoural calcinosis in a young woman.
    Nephrology (Carlton, Vic.), 2016, Volume: 21, Issue:3

    Topics: Calcinosis; Chelating Agents; Female; Hand Joints; Humans; Joint Diseases; Kidney Failure, Chronic;

2016
Topical Sodium Thiosulfate: A Treatment for Calcifications in Hyperphosphatemic Familial Tumoral Calcinosis?
    The Journal of clinical endocrinology and metabolism, 2016, Volume: 101, Issue:7

    Topics: Administration, Topical; Adult; Calcinosis; Child; Female; Humans; Hyperostosis, Cortical, Congenita

2016
Intravenous sodium thiosulfate for treating tumoral calcinosis associated with systemic disorders: Report of four cases.
    Joint bone spine, 2017, Volume: 84, Issue:3

    Topics: Administration, Intravenous; Calcinosis; Chelating Agents; Humans; Thiosulfates

2017
Bone scan findings in metastatic calcification from calciphylaxis.
    Clinical nuclear medicine, 2008, Volume: 33, Issue:7

    Topics: Bone and Bones; Calcinosis; Calciphylaxis; Female; Humans; Ischemia; Kidney Failure, Chronic; Middle

2008
Sodium thiosulfate prevents vascular calcifications in uremic rats.
    Kidney international, 2008, Volume: 74, Issue:11

    Topics: Animals; Aortic Diseases; Bone and Bones; Calcinosis; Calcium; Kidney Diseases; Rats; Renal Circulat

2008
Topical sodium thiosulfate therapy for leg ulcers with dystrophic calcification.
    Archives of dermatology, 2008, Volume: 144, Issue:12

    Topics: Administration, Topical; Adult; Calcinosis; Female; Humans; Immunosuppressive Agents; Leg Ulcer; Lup

2008
Successful treatment of calcific uremic arteriolopathy in a pediatric dialysis patient.
    Pediatric nephrology (Berlin, Germany), 2010, Volume: 25, Issue:2

    Topics: Adolescent; Antioxidants; Arterial Occlusive Diseases; Calcinosis; Combined Modality Therapy; Granul

2010
Sodium thiosulfate delays the progression of coronary artery calcification in haemodialysis patients.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2010, Volume: 25, Issue:6

    Topics: Aged; Bone Density; Calcinosis; Chelating Agents; Coronary Artery Disease; Disease Progression; Fema

2010
The effect of topical sodium thiosulfate in experimentally induced myringosclerosis.
    The Laryngoscope, 2010, Volume: 120, Issue:7

    Topics: Administration, Topical; Animals; Calcinosis; Rats; Rats, Wistar; Thiosulfates; Tympanic Membrane

2010
A novel treatment for ulcerative calcinosis cutis.
    Journal of drugs in dermatology : JDD, 2011, Volume: 10, Issue:9

    Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Calcinosis; Female; Humans; Male; Skin Diseases;

2011
A novel treatment for ulcerative calcinosis cutis.
    Journal of drugs in dermatology : JDD, 2011, Volume: 10, Issue:9

    Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Calcinosis; Female; Humans; Male; Skin Diseases;

2011
A novel treatment for ulcerative calcinosis cutis.
    Journal of drugs in dermatology : JDD, 2011, Volume: 10, Issue:9

    Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Calcinosis; Female; Humans; Male; Skin Diseases;

2011
A novel treatment for ulcerative calcinosis cutis.
    Journal of drugs in dermatology : JDD, 2011, Volume: 10, Issue:9

    Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Calcinosis; Female; Humans; Male; Skin Diseases;

2011
Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis.
    The Journal of pediatrics, 2012, Volume: 160, Issue:3

    Topics: Abatacept; Adolescent; Anti-Inflammatory Agents; Antioxidants; Calcinosis; Chelating Agents; Dermato

2012
Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis.
    The Journal of pediatrics, 2012, Volume: 160, Issue:3

    Topics: Abatacept; Adolescent; Anti-Inflammatory Agents; Antioxidants; Calcinosis; Chelating Agents; Dermato

2012
Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis.
    The Journal of pediatrics, 2012, Volume: 160, Issue:3

    Topics: Abatacept; Adolescent; Anti-Inflammatory Agents; Antioxidants; Calcinosis; Chelating Agents; Dermato

2012
Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis.
    The Journal of pediatrics, 2012, Volume: 160, Issue:3

    Topics: Abatacept; Adolescent; Anti-Inflammatory Agents; Antioxidants; Calcinosis; Chelating Agents; Dermato

2012
Dramatic diminution of a large calcification treated with topical sodium thiosulfate.
    Arthritis and rheumatism, 2012, Volume: 64, Issue:11

    Topics: Administration, Topical; Antioxidants; Calcinosis; Child; Humans; Hyperostosis, Cortical, Congenital

2012
Successful management of critical limb ischemia with intravenous sodium thiosulfate in a chronic hemodialysis patient.
    Clinical nephrology, 2006, Volume: 66, Issue:2

    Topics: Calcinosis; Calciphylaxis; Fingers; Humans; Infusions, Intravenous; Ischemia; Male; Middle Aged; Ren

2006
Sodium thiosulfate in the treatment of tumoral calcifications in a hemodialysis patient without hyperparathyroidism.
    Nephron, 1996, Volume: 72, Issue:2

    Topics: Antioxidants; Calcinosis; Chelating Agents; Female; Humans; Hyperparathyroidism; Joint Diseases; Kid

1996
Sodium thiosulfate treatment of tumoral calcinosis in patients with end-stage renal disease.
    Renal failure, 1990, Volume: 12, Issue:4

    Topics: Calcinosis; Female; Humans; Kidney Failure, Chronic; Male; Renal Dialysis; Thiosulfates

1990